Skip to Content
Investing Specialists

Weekly Wrap: Our 529 Ratings and 15 Top-Quality Stocks

We recap the week on and note the most popular stocks, funds, and exchange-traded funds.

Editor's Picks
Rating the Top 529 College Savings Plans
We upgrade nine plans and downgrade eight, shaking up our Gold and Silver ratings.

15 Top-Quality Stocks
These names were recently added to the Morningstar Wide Moat Focus Index.

3 Good Reasons to Sell a Fund
How to make the call.

It's Open Enrollment Season. Have You Taken a Good Look at an HSA?
For high-income investors who are maxing out other tax-sheltered accounts, the high-deductible healthcare plan/HSA combo is close to a no-brainer.

Earnings Updates
Tide Has Turned on P&G's Sales Course, Shares Pricey
Wide-moat Procter & Gamble chalked up another quarter of strong sales and profit gains.

Tariffs Drive Retail Disruption at Narrow-Moat Hasbro
We view shares as overvalued, and we plan to increase our fair value estimate.

Texas Instruments Sees Stronger Trade Headwinds
We'd seek a wider margin of safety before investing in this wide-moat firm.

Tesla's Surprise Profit Blows Away Consensus
Tesla is a volatile name and fair value estimate changes may be frequent as its story changes.

Microsoft Reports Good Results and Mixed Guidance
We believe wide-moat Microsoft is firing on all cylinders and remains a relatively safe harbor.

Chipotle: More Than a Comeback Story, but Shares Rich
Our optimism is tempered by a market valuation that assumes unrealistic long-term expectations.

One-Day Shipping Weighs on Amazon
The wide-moat firm remains our top pick in online retail, with the pullback offering an entry point to invest.

Product Bugs Hinder Twitter's Q3 Growth
We recommend waiting for an additional margin of safety before investing in this very-high-uncertainty name.

Competition Hits McDonald's U.S. Comps
Our fair value estimate for the wide-moat firm remains intact, and shares are modestly undervalued.

Raising Our Fair Value Estimate for Biogen
We assign a 30% probability of approval of the wide-moat firm's Alzheimer's drug.

To view this article, become a Morningstar Basic member.

Register for Free